Bank of New York Mellon Corp Has $165.20 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bank of New York Mellon Corp lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,563,905 shares of the medical equipment provider’s stock after selling 2,381 shares during the period. Bank of New York Mellon Corp’s holdings in Zimmer Biomet were worth $165,195,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $25,000. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at approximately $28,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $35,000. Finally, Kentucky Trust Co acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on ZBH shares. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Stifel Nicolaus upped their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 0.8 %

ZBH opened at $104.03 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a fifty day moving average of $105.78 and a 200-day moving average of $107.40. The stock has a market cap of $20.71 billion, a PE ratio of 23.38, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 earnings per share. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet’s payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.